Global Thalassemia Market Projected To Augment At A CAGR Of Approximately 10.2% During 2019–2025

As per analysts at Zion Market Research, the global thalassemia market is estimated to advance at a CAGR of over 10.2% during the forecasted period 2019–2026. Large population, surge in awareness related to obtainable treatment alternatives, and augment in the demand for enhanced curative gene treatments are some of the key aspects expected to propel the market. Thalassemia is an unusual hereditary blood disorder that is characterized by the formation of atypical hemoglobin, which is accountable for the decay of red blood cells, causing anemia. At present, iron chelation and blood transfusion therapies are the only treatment alternatives available. This offers ample opportunities in the market for the advancement of a universal therapeutic treatment for thalassemia.

Some of the leading players in the market are Acceleron Pharma, Inc.; bluebird bio; GlaxoSmithKline plc; Celgene Corporation; Gamida Cell; Incyte Corporation; La Jolla Pharmaceutical Company; Kiadis Pharma; and IONIS Pharmaceuticals.

Augmented Research & Development Funding By Key Players Will Boost The Growth Of Global Thalassemia Market

The global thalassemia market is mainly driven by aspects like increasing patients from all age groups having thalassemia. In addition, continuously transforming drug pipelines and augmenting number of patented drugs for the treatment of thalassemia will also stimulate the entire thalassemia treatment industry. Furthermore, augmenting investment in healthcare infrastructure in the emerging countries will also stimulate the thalassemia market in the upcoming years. Whilst, the augmenting clinical trials for advancing new combination drugs and increasing research & development funding and speculations on healthcare by the administrations of developed & developing economies, and unmet requirements for efficient treatments control the market growth over the estimated period. Furthermore, key trends in the market include surging drug pipeline, expanding scope of gene therapy, and rising number of people with thalassemia.

The global thalassemia market is bifurcated on the basis of thalassemia type, therapeutic class, pipeline, end-user, and regional analysis. Based on the thalassemia type, the market is divided into alpha thalassemia and beta thalassemia. Based on the therapeutic class, the market is divided into Exjade/Jadenu (deferasirox) and iron chelating drugs. Based on the pipeline, the market is divided into gene therapy and LentiGlobin. Based on the end-user, the market is divided into clinics, hospitals, laboratories, and research institutes.

The Asia Pacific Region Estimated To Witness Lucrative Growth In The Global Thalassemia Market

Based on geographical analysis, the global thalassemia market is divided into North America, Europe, Latin America, Asia Pacific, and Middle East & Africa. The North American region is likely to dominate the global market during the forecasted period. The region holds major share due to the constant technological advancements by the surging research & development investments by the key players & administration and augmenting investment by several leading players in this region. In addition, the augmenting number of patients suffering from thalassemia across the U.S. is expected to spur the growth across the North America region. Nevertheless, the Asia Pacific region is also projected to be a lucrative market over the estimated period. The amplifying number of patients with thalassemia and increased administration expenditure for advancing healthcare infrastructure are the key aspects that will boost the thalassemia market across the Asia Pacific region throughout forecasted years.

Browse the full “Global Thalassemia Market - by Type (Hb Bart Syndrome Or Hemoglobin Bart Hydrops Fetalis Syndrome, Silent Carrier State, Hbh Disease, Trait), by Diagnosis (Prenatal Testing, Perinatal Testing, Pre-Implantation), by Treatment (Iron Chelation, Blood Transfusions, Stem Cell Transplant Or Bone Marrow, Gene Therapy Surgery), by End-User (Pharmaceutical Industries, Biotechnological Laboratories, Hospitals, Educational Research Institutes, Diagnostic Laboratories, Others), and by Region: Latest Industry Insights, Comprehensive Analysis and Forecast, 2019 – 2026.” Report at https://www.zionmarketresearch.com/report/thalassemia-market

The global thalassemia market is segmented as follows:

By thalassemia type:

• Alpha Thalassemia
• Beta Thalassemia

By therapeutic class:

• Exjade/Jadenu (deferasirox)
• Iron Chelating Drugs

By pipeline:

• LentiGlobin
• Gene Therapy

By end-user:

• Clinics
• Hospitals
• Laboratories
• Research Institutes

By region:

• North America
  • The U.S.
  • Canada
• Europe
  • France
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa

About Us:

Zion Market Research is an obligated company. We create futuristic, cutting-edge, informative reports ranging from industry reports, the company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client’s needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us.

Contact Us:

Zion Market Research
244 Fifth Avenue, Suite N202
New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll-Free No.1-855-465-4651
Email: sales@zionmarketresearch.com
Website: https://www.zionmarketresearch.com